Carcinoma of the endometrium

Drugs

Volumn 61, Issue 10, 2001, Pages 1395-1405

  Southcott, B M ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; TAMOXIFEN;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; ENDOMETRIUM CARCINOMA; HORMONE SUBSTITUTION; HUMAN; REVIEW;

EID: 0034865048     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161100-00003     Document Type: Review

References (57)

1. Age related factors in cancers of the breast, ovary and endometrium
2. Menstrual span - Increases in risk as menstruation span increases
3. Obesity, diet, endogenous estrogens and the risk of hormone sensitive cancer
4. Cigarette smoking and the risk of endometrial cancer
5. Smoking, body weight and early stage endometrial cancer
6. Cigarette smoking and the risk of family reproductive cancer
7. Post menopausal smoking, estrogen replacement therapy and the risk of endometrial cancer
8. The effects of hormone replacement therapy on endometrial histology in postmenopausal women: The postmenopausal estrogen/progestin intervention trial (PEPI)
9. Risk of endometrial cancer following estrogen replacement therapy with and without progestins
10. Endometrial cancer following treatment for breast cancer - A case control study in Denmark
11. The potentially oncogenic effect of tamoxifen on the endometrium
12. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Assessment of liver and endometrial cancer risk following tamoxifen
13. Fat intake, obesity and cancer of the breast and endometrium
14. Endometrial cancer associated with pregnancy - A report of 3 cases and a review of the literature
15. The prognostic significance of P53, PCNA and C-erb B-2 in endometrial adenocarcinoma
16. P53 staining as a prognostic indicator in endometrial carcinoma
17. P53 staining as a prognostic indicator in endometrial carcin. Predicting pelvis lymph node metastases in endometrial cancer
18. Predictors of recurrence in Surgical Stage II endometrial adenocarcinoma
19. Serial serum CA125 measurements for evaluation of recurrences in patients with endometrial carcinoma
20. Low levels of cathepsin dose associated with poor prognosis in endometrial cancer
21. High metallothionein expression is associated with features predictive of aggressive behaviour on endometrial cancer
22. The molecular biology of endometrial cancer. Division of Gynaecological Oncology
23. Hysteroscopy for diagnosis and treatment of endometrial adenocarcinoma precursors. A review of the literature
24. Outpatient endometrial biopsy - The pipelle
25. Pre-operative assessment of myometrial invasion of endometrial carcinoma by transvaginal ultra sonography
26. Embolic vascular seeding of endometrial adenocarcinoma; a complication of hysteroscopic endometrial biopsy
27. The value of pre or post operative treatment by radium for carcinoma of the uterus
28. Endometrial cancer: Changing concepts in therapy
29. Surgicopathologic staging of endometrial adenocarcinoma
30. Routine retroperitoneal drainage is not required for uncomplicated pelvic lymphadenopathy for uterine cancer
31. Endometrial carcinoma: Adjuvant locoregional therapy
32. Early uterine body carcinoma: Has post-operative vaginal irradiation any value?
33. A phase III randomised study of surgery plus adjunctive radiation therapy in intermediate risk endometrial adenocarcinoma (GOG No99)
34. Surgery and post operative radiotherapy versus surgery alone for patients with Stage I endometrial carcinoma
35. Endometrial carcinoma: Does the addition of intra cavity vault caesium to external beam therapy post-operatively result in improved control or increased morbidity?
36. A prospective trial comparing hysterectomy, hysterectomy plus vaginal radium and uterine radium plus hysterectomy in Stage I endometrial carcinoma
37. Adjunctive radiation therapy in the management of Stage I cancer of the endometrium
38. Post operative irradiation and prognostic parameters in Stage I endometrial carcinoma
39. Radiotherapy in poor risk patients with stage I cancer of the endometrium: Results of not giving external beam radiotherapy
40. Treatment of recurrent metastatic adenocarcinomas of the endometrium with cisplatin, doxombicin, cyclophosphamide and medroxyprogestcrone acetate
41. Persistent chemo sensitivity to platinum and/or paclitaxel in metastatic endometrial carcinoma
42. Endometrial cancer cell lines are sensitive to Paclitaxel
43. Adjuvant progestin therapy in the primary definitive treatment of endometrial cancer
44. Progestin alone as primary treatment of endometrial carcinoma in pre-menopausal women
45. Treatment of endometrial cancer with radiation alone
46. The value of and indications for radiotherapy in endometrial carcinoma
47. Results of treatment of locally advanced carcinoma of the endometrium
48. Endometrial carcinoma metastatic to scalp: A case report and literature review
49. Endometrial carcinoma presenting with an isolated osscous metastasis: A case report and review of literature
50. Metastatic endometrial cancer in the foot: A case report
51. Metastatic endometrial adenocarcinomas to the skin of the toe
52. Endometrial carcinoma arising in the scar of caesarean section